Dr Michot on the Importance of the OLYMPIA-3 Study of Odronextamab Plus Chemo in DLBCL

“[This is the] first study to evaluate the replacement of rituximab with odronextamab, which is a [CD20/CD3-targeted] bispecific antibody, in combination with CHOP for patients with previously untreated DLBCL.”

Jean-Marie Michot, MD, a medical doctor in the Department of Hematology and Innovative Drugs at the Institut de Cancérologie Gustave Roussy, discussed the potential clinical relevance of the findings from part 1A of the phase 3 OLYMPIA-3 study (NCT06091865) investigating odronextamab (Ordspono) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).